Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun Lu

Showing results (531-540 of 661) with videos related to

Pageof 67
Sort By:
Signal Transduction and Targeted Therapy|December 15, 2024
Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)Xinghao Ai, Bo Jia, Zhiyi He, et al.
BMC Medicine|February 1, 2022
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trialZhengbo Song, Yuping Li, Shiqing Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialYi-Long Wu, Shun Lu, Ying Cheng, et al.
Cell Reports. Medicine|December 5, 2023
Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinomaJianchun Duan, Yun Zhang, Ran Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2023
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical TrialEdward B Garon, Shun Lu, Yasushi Goto, et al.
Ecotoxicology and Environmental Safety|June 24, 2025
The relationship between prenatal perfluorine and polyfluoroalkyl substances (PFAS) exposure and infant neurodevelopment: Modifying effects of DHA revisedTing-Ting Jiang, Lian-Man Lei, Xia-Yu Zhang, et al.
Current Cancer Drug Targets|June 30, 2015
The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal PathwaysZhan Liao, Guoxin Nan, Zhengjian Yan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2011
Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approachManuel Salto-Tellez, Ming-Sound Tsao, Jin-Yuan Shih, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parametersSolange Peters, Walter Weder, Urania Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2021
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)Ying Cheng, Tony S Mok, Xiangdong Zhou, et al.
Pageof 67

Showing results (531-540 of 661) with videos related to

Sort By:
Pageof 67
Signal Transduction and Targeted Therapy|December 15, 2024
Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)Xinghao Ai, Bo Jia, Zhiyi He, et al.
BMC Medicine|February 1, 2022
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trialZhengbo Song, Yuping Li, Shiqing Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialYi-Long Wu, Shun Lu, Ying Cheng, et al.
Cell Reports. Medicine|December 5, 2023
Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinomaJianchun Duan, Yun Zhang, Ran Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2023
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical TrialEdward B Garon, Shun Lu, Yasushi Goto, et al.
Ecotoxicology and Environmental Safety|June 24, 2025
The relationship between prenatal perfluorine and polyfluoroalkyl substances (PFAS) exposure and infant neurodevelopment: Modifying effects of DHA revisedTing-Ting Jiang, Lian-Man Lei, Xia-Yu Zhang, et al.
Current Cancer Drug Targets|June 30, 2015
The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal PathwaysZhan Liao, Guoxin Nan, Zhengjian Yan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2011
Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approachManuel Salto-Tellez, Ming-Sound Tsao, Jin-Yuan Shih, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parametersSolange Peters, Walter Weder, Urania Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2021
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)Ying Cheng, Tony S Mok, Xiangdong Zhou, et al.
Pageof 67